"[Buprenorphine] is a tremendously powerful medication, saves many lives and prevents overdose, but there is a risk of misuse and diversion, albeit pretty low," says Dr. Francis Levin.
“Our findings open the door for the development of treatments to target specific symptoms of psychosis depending on an individual subject’s symptom profile," says Guillermo Horga, MD, PhD
“The efficacy and safety profile of CAPLYTA approved by the FDA, offers healthcare providers an important new option for treating people living with schizophrenia,” said Dr. Jeffrey A. Lieberman.
The study suggests that some of the ways schools cope with student suicides might prove useful in the aftermath of a school shooting, Dr. Mark Olfson said.
Dr. Elias Dakwar said he became interested in ketamine as a potential treatment for alcohol use disorder after seeing good results from using the drug to treat cocaine addiction.
Researchers findings at Columbia University Vagelos College of Physicians and Surgeons and New York State Psychiatric Institute could lead to a new approach to the treatment of alcohol use disorder.
"The rate at which individuals relapsed and overdosed after ending treatment was alarmingly high, suggesting that discontinuing buprenorphine is a life-threatening event," said Dr. Williams.
“What I am really creeped out about is the marketing of CBD as a medicine—and that’s really what it’s being marketed for—when there is no good data,” said Dr. Margaret Haney.